145 related articles for article (PubMed ID: 21325484)
41. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
[TBL] [Abstract][Full Text] [Related]
42. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
[TBL] [Abstract][Full Text] [Related]
43. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
44. Potential and clinical translation of oncolytic measles viruses.
Robinson S; Galanis E
Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
[TBL] [Abstract][Full Text] [Related]
45. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
[TBL] [Abstract][Full Text] [Related]
46. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
47. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
48. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
49. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
50. Measles virus in cancer therapy.
Mühlebach MD
Curr Opin Virol; 2020 Apr; 41():85-97. PubMed ID: 32861945
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
52. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.
Patel B; Dey A; Ghorani E; Kumar S; Malam Y; Rai L; Steele AJ; Thomson J; Wickremasinghe RG; Zhang Y; Castleton AZ; Fielding AK
Mol Ther; 2011 Jun; 19(6):1034-40. PubMed ID: 21427708
[TBL] [Abstract][Full Text] [Related]
53. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
[TBL] [Abstract][Full Text] [Related]
54. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
55. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression.
Richard V; Lairmore MD; Green PL; Feuer G; Erbe RS; Albrecht B; D'Souza C; Keller ET; Dai J; Rosol TJ
Am J Pathol; 2001 Jun; 158(6):2219-28. PubMed ID: 11395400
[TBL] [Abstract][Full Text] [Related]
56. Expression of tumor invasion factors determines systemic engraftment and induction of humoral hypercalcemia in a mouse model of adult T-cell leukemia.
Parrula C; Zimmerman B; Nadella P; Shu S; Rosol T; Fernandez S; Lairmore M; Niewiesk S
Vet Pathol; 2009 Sep; 46(5):1003-14. PubMed ID: 19429977
[TBL] [Abstract][Full Text] [Related]
57. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
58. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
59. Opportunities to debottleneck the downstream processing of the oncolytic measles virus.
Loewe D; Dieken H; Grein TA; Weidner T; Salzig D; Czermak P
Crit Rev Biotechnol; 2020 Mar; 40(2):247-264. PubMed ID: 31918573
[TBL] [Abstract][Full Text] [Related]
60. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]